General Proximity - About the company
General Proximity is a seed company based in San Francisco (United States), founded in 2023 by Armand B Cognetta III. It operates as a Developer of next generation of induced-proximity medicines. General Proximity has raised $16M in funding. The company has 161 active competitors, including 66 funded and 9 that have exited. Its top competitors include companies like Evotec, DNAnexus and Insitro.
Company Details
Developer of next generation of induced-proximity medicines. The company uses the OmniTAC drug discovery engine which yields molecules that co-opt existing cellular machinery to overcome exigent therapeutic challenges for oncology indications.
- Website
- www.generalproximity.bio/
- Social
- Email ID
- *****@generalproximity.bio
Key Metrics
Founded Year
2023
Location
San Francisco, United States
Stage
Seed
Total Funding
$16M in 2 rounds
Latest Funding Round
Investors
Ranked
21st among 161 active competitors
Employee Count
22 as on May 31, 2026
Sign up to download General Proximity's company profile
General Proximity's funding and investors
General Proximity has raised a total funding of $16M over 2 rounds. Its first funding round was on Jan 04, 2025. Its latest funding round was a Seed round on May 04, 2026 for $*****. 1 investor participated in its latest round. General Proximity has 7 institutional investors and 5 angel investors.
Here is the list of recent funding rounds of General Proximity:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 04, 2026 | 8425535 | Seed | 8108910 | 7626430 | 5682471 | 4308068 |
Jan 04, 2025 | 9640749 | Seed | 7028656 | 4934447 | 6202151 |
Access funding benchmarks and valuations. Sign up today!View details of General Proximity's funding rounds and investors
General Proximity's founders and board of directors
Founder? Claim ProfileThe founders of General Proximity is Armand B Cognetta III. Armand B Cognetta III is the CEO of General Proximity.
Here are the details of General Proximity's key team members:
- Armand B Cognetta III: Founder & CEO of General Proximity. Contact Info: 1 email address
View details of General Proximity's Founder profiles and Board Members
General Proximity's employee count trend
General Proximity has 22 employees as of May 26. Here is General Proximity's employee count trend over the years:
Uncover General Proximity's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
General Proximity's Competitors and alternates
Top competitors of General Proximity include Evotec, DNAnexus and Insitro. Here is the list of Top 10 competitors of General Proximity, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AI-driven life science company accelerating drug discovery and development | $25.1M | 76/100 | ||
2nd |  DNAnexus 2009, Mountain View (United States), Series H | Provider of cloud-based genome informatics & data management platform | $473M | 70/100 | |
3rd |  Insitro 2018, San Francisco (United States), Series C | Developer of machine learning platform for drug discovery and development | $643M | 70/100 | |
4th | Immunai Technologies 2018, United States, Series B | Developer of next-generation of immunomodulatory therapeutics | $295M | 66/100 | |
5th |  Asimov 2017, Boston (United States), Series B | Provider of integrated suite for advanced genetic design and manufacturing | $234M | 65/100 | |
6th | Metagenomi 2016, Berkeley (United States), Public | Digital gene editing technologies for drug development | $376M | 64/100 | |
7th | _1569310612679.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kinomica 2017, Macclesfield (United Kingdom), Series A | Provider of a bioinformatics platform for the development of precision medicine | $5.16M | 64/100 | |
8th | Relation 2019, London (United Kingdom), Seed | AI-based drug development tools for researchers | $116M | 64/100 | |
9th |  Somite 2023, Boston (United States), Series A | AI-driven platform to produce human tissue for cell-based therapies | $60M | 63/100 | |
10th |  Form Bio 2022, Austin (United States), Series A | Cloud-based data management tool for providers | $30M | 60/100 | |
21st |  General Proximity 2023, San Francisco (United States), Seed | Developer of next generation of induced-proximity medicines | $16M | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on General Proximity's competitors? Click here to see the top ones
General Proximity's Investments and acquisitions
General Proximity has made no investments or acquisitions yet.
Reports related to General Proximity
Here is the latest report on General Proximity's geography:
News related to General Proximity
Media has covered General Proximity for 1 event in last 1 year.
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about General Proximity
Explore our recently published companies
- Centerra Co-op - Ashtabula based, 2016 founded, Seed company
- Meaningful Vision - London based, Unfunded company
- Birda - London based, 2017 founded, Unfunded company
- Edinburgh Street Food - Edinburgh based, 2023 founded, Unfunded company
- Chantely Beauty - Bengaluru based, 2025 founded, Unfunded company
- FAB Partners - 2016 founded, Unfunded company
